10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

Amendment No. 1

x Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended April 30, 2013.

¨ Transition report under Section 13 or 15(d) of the Exchange Act

For the transition period from _____________ to _____________.

Commission file number 000-28761

CARDIOGENICS HOLDINGS INC.

(Exact name of registrant as specified in its Charter)

Nevada	88-0380546
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

6295 Northam Drive, Unit 8

Mississauga, Ontario L4V 1WB

(Address of Principal Executive Offices)

(905) 673-8501

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer and “smaller reporting company” in Rule 12b-2 or the Exchange Act. (Check one):

	Large Accelerated filer	¨	Accelerated Filer	¨
	Non-Accelerated Filer	¨	Smaller Reporting Company	x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

Yes ¨ No x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    

Yes x No ¨

As of June 12, 2013 the Registrant had the following number of shares of its capital stock outstanding: 32,499,239 shares of Common Stock and 1 share of Series 1 Preferred Voting Stock, par value $0.0001, representing 13 exchangeable shares of the Registrant’s subsidiary, CardioGenics ExchangeCo Inc., which are exchangeable into 24,176,927 shares of the Registrant’s Common Stock.

EXPLANATORY NOTE

The sole purpose of this amendment to CardioGenics Holdings Inc.’s quarterly report on Form 10-Q for the period ended April 30, 2013, filed with the Securities Exchange Commission on June 20, 2013 (the “Form 10-Q”), is to furnish the interactive data files set forth in Exhibit 101 in accordance with Rule 405 of Regulation S-T.

No other changes have been made to the Form 10-Q. This amendment speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Form 10-Q.

ITEM 6. EXHIBITS

(a) Exhibits

See the Exhibit Index following the signature page to this Form 10-Q/A.

2

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOGENICS HOLDINGS INC.
Date: August 7, 2013	By:	/s/ Yahia Gawad
		Name:  Yahia Gawad
		Title:  Chief Executive Officer
Date: August 7, 2013	By:	/s/ James Essex
		Name:  James Essex
		Title:  Chief Financial Officer

EXHIBIT INDEX

*31.1	Section 302 Certification of Chief Executive Officer
*31.2	Section 302 Certification of Chief Financial Officer
*32.1	Section 906 Certification of Chief Executive Officer and Chief Financial Officer
†101	The following materials from CardioGenics Holdings Inc.’s Form 10-Q for the quarter ended April 30, 2013, formatted in eXtensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets, (ii) Consolidated Statements of Operations (Unaudited), (iii) Condensed Consolidated Statements of Comprehensive Loss (Unaudited), (iv) Condensed Consolidated Statements of Changes in Deficiency (Unaudited), (v) Condensed Consolidated Statements of Cash Flows (Unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (Unaudited). Furnished herewith.
	__________________
	* Filed or furnished with the initial filing of this Form 10-Q filed on June 20, 2013.
	† Pursuant to Rule 406T of Regulation S-T, the interactive data files included in Exhibit 101 are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

XML

Debentures Payable

6 Months Ended

Apr. 30, 2013

Debt Disclosure [Abstract]

Debentures Payable

10. Debentures Payable

In February 2013, shareholder loans were converted on a dollar-for-dollar basis for Series A Convertible Debenture Units (the “A Units”). Each A Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 2 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at any time up to three years.

A summary of the Debentures at April 30, 2013 is as follows:

	April 30, 2013			October 31, 2012
Convertible Debentures Payable, interest at 10% per annum to maturity at February 27, 2016	$	300,393		$	-
Debt Discount - value attributable to conversion feature attached to notes		(95,760	)		-
Total		204,633			-
Less: Current portion		-			-
Total Long-term portion	$	204,633		$	-

XML

Net Loss Per Share - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013	Apr. 30, 2012
Earnings Per Share Disclosure [Line Items]
Incremental shares excluded from computation of diluted earning per share	2,917,085	9,834,969	2,917,085	9,834,969

XML

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended		185 Months Ended
	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013
Revenue	$ 0	$ 0	$ 0	$ 1,136	$ 10,173
Operating Expenses
Depreciation and Amortization of Property and Equipment	3,443	4,539	6,967	9,094	226,711
Amortization of Patent Application Costs	1,695	1,260	3,429	2,560	22,722
Write-off of Patent Application Costs	0	0	0	0	239,530
General and Administrative	92,915	187,325	205,647	361,488	8,622,678
Write-off of Goodwill	0	0	0	0	12,780,214
Research and Product Development, Net of Investment Tax Credits	95,042	192,694	198,486	348,738	4,348,819
Cost of Settlement of Lawsuit	0	0	0	0	1,753,800
Total operating expenses	193,095	385,818	414,529	721,880	27,994,474
Operating Loss	(193,095)	(385,818)	(414,529)	(720,744)	(27,984,301)
Other Expenses (Income)
Interest Expense and Bank Charges (Net)	32,892	6,015	36,716	9,485	2,195,024
Loss (Gain) on Change in Fair Value of Derivative Liability	(10,781)	0	(10,781)	0	12,410,242
Loss (Gain) on Foreign Exchange Transactions	(4,116)	2,238	3,923	(19,126)	194,266
Total other expenses (income)	17,995	8,253	29,858	(9,641)	14,799,532
Loss from Continuing Operations	(211,090)	(394,071)	(444,387)	(711,103)	(42,783,833)
Discontinued Operations
Gain on Sale of Subsidiary	0	0	0	0	90,051
Loss from Discontinued Operations	0	0	0	0	(127,762)
Net Loss	(211,090)	(394,071)	(444,387)	(711,103)	(42,821,544)
Net Loss attributable to non-controlling interest	(1,231)	(2,368)	(2,721)	(4,431)	(340,655)
Net Loss attributable to CardioGenics Holdings Inc.	$ (209,859)	$ (391,703)	$ (441,666)	$ (706,672)	$ (42,480,889)
Basic and Fully Diluted Net Loss per Common Share attributable to CardioGenics Holdings Inc. Shareholders	$ 0.00	$ (0.01)	$ (0.01)	$ (0.01)
Weighted-average shares of Common Stock outstanding	56,676,166	55,626,166	56,676,166	55,626,166

XML

Summary of Significant Accounting Policies.

6 Months Ended

Apr. 30, 2013

Accounting Policies [Abstract]

Summary of Significant Accounting Policies.

3. Summary of Significant Accounting Policies.

Recent Accounting Pronouncements

In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 as of November 1, 2013.

In February 2013, the Financial Accounting Standards Board (“FASB”) issued guidance requiring disclosure of amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present either on the face of the condensed consolidated statements of operations or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts not reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This guidance is effective prospectively for the Company for annual and interim periods beginning January 1, 2013. The Company believes that the impact of this standard has not had a material impact on its consolidated financial statements.

Derivative Instruments

The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the condensed consolidated balance sheets as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date.

XML

Subsequent Events

6 Months Ended

Apr. 30, 2013

Subsequent Events [Abstract]

Subsequent Events

17. Subsequent Events

(i) In May 2013, the $200,000 advance included in the condensed consolidated balance sheet at April 30, 2013, together with a further advance of $300,000 from the same third party in May 2013, was exchanged on a dollar-for-dollar basis for Series B Convertible Debenture Units (the “B Units”). Each B Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed on conversion of the debentures at a price of $0.15 per share exercisable at any time during the term of the warrant.

(ii) In June 2013, certain officers of the Company purchased $155,000 in Series B Convertible Debenture Units (the “B Units”). Each B Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the conversion of the debentures at a price of $0.15 per share exercisable at any time during the term of the warrant.

XML

Subsequent Event - Additional Information (Detail) (USD $)	1 Months Ended	6 Months Ended
	May 30, 2013	Apr. 30, 2013	Jun. 30, 2013
Subsequent Event [Line Items]
Debt instrument, interest rate, stated percentage		10.00%
Debt instrument term		3 years
Debt instrument, convertible, conversion price	$ 0.15	$ 0.25	$ 0.15
Share price		$ 0.25
Advances From Unrelated Third Party	$ 300,000	$ 200,000
Convertible Debt			$ 155,000

XML

Stock Based Compensation

6 Months Ended

Apr. 30, 2013

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Stock Based Compensation

11. Stock Based Compensation

Stock-based employee compensation related to stock options for the six months ended April 30, 2013 and 2012 amounted to $-0-.

The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:

			Weighted
			Average
			Exercise
	Options		Price
Outstanding – October 31, 2011		30,000	$	0.90
Granted		▬		▬
Forfeited/Expired		▬		▬
Exercised		▬		▬
Outstanding – October 31, 2012		30,000	$	0.90
Granted		▬		▬
Forfeited/Expired		▬		▬
Exercised		▬		▬
Outstanding – April 30, 2013		30,000	$	0.90

Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at April 30, 2013.

XML

Summary of Common Stock Options Granted, Forfeited or Expired and Exercised under Plan (Detail) (USD $)	6 Months Ended	12 Months Ended
	Apr. 30, 2013	Oct. 31, 2012
Options
Outstanding beginning balance	30,000	30,000
Granted	0	0
Forfeited/Expired	0	0
Exercised	0	0
Outstanding ending balance	30,000	30,000
Weighted Average Exercise Price
Beginning balance	$ 0.90	$ 0.90
Granted	$ 0	$ 0
Forfeited/Expired	$ 0	$ 0
Exercised	$ 0	$ 0
Ending balance	$ 0.90	$ 0.90

XML

Notes Payable - Additional Information (Detail) (USD $)	0 Months Ended
	Nov. 19, 2012	Mar. 27, 2013
Notes Payable [Line Items]
Line of credit facility, maximum borrowing capacity	$ 350,000
Line of credit facility, current borrowing capacity	50,000
Line of credit facility original issue discount	50,000
Line of credit facility, interest rate during period	5.00%
Line of credit facility, description	the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion.
Line of credit facility common stock outstanding percentage	4.99%
Line of credit facility, amount outstanding		$ 25,000

XML

Fair Value Measurements (Tables)

6 Months Ended

Apr. 30, 2013

Compensation and Retirement Disclosure [Abstract]

Fair Value, Liabilities Measured on Recurring Basis

The following table summarizes the financial liabilities measured at fair value on a recurring basis as of April 30, 2013, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value:

	Quoted Prices in								Total Increase (Reduction)
	Active Markets for		Significant Other		Significant				in Fair Value
Balance Sheet	Identical Assets or		Observable Inputs		Unobservable		April 30, 2013		Recorded at
Location	Liabilities (Level 1)		(Level 2)		Inputs (Level 3)		Total		April 30, 2013
Liabilities:
Derivative liability – on Notes Payable	$	-	$	-	$	64,219	$	64,219	$	10,781

Changes In Fair Value Of Derivative Liability

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the six month period ended April 30, 2013.

Balance at beginning of period	$	-
Additions to derivative instruments		75,000
Change in fair value of derivative liabilities		(10,781	)
Balance at end of period	$	64,219

XML

Notes Payable (Tables)

6 Months Ended

Apr. 30, 2013

Notes Payable [Abstract]

Schedule of Debt

A summary of the Notes at April 30, 2013 is as follows:

	April 30, 2013			October 31, 2012
Convertible Note Payable, interest at 5% per annum to maturity at November 19, 2014	$	50,000		$	-
Convertible Note Payable, interest at 5% per annum to maturity at March 27, 2014		25,000			-
Debt Discount - value attributable to conversion feature attached to notes, net of accumulated amortization of $22,900		(52,100	)		-
Total		22,900			-
Less: Current portion		22,900			-
Total Long-term portion	$	-		$	-

XML

Debentures Payable (Parenthetical) (Detail) (Convertible Debentures Payable, February 27, 2016)	6 Months Ended	12 Months Ended
	Apr. 30, 2013	Oct. 31, 2012
Convertible Debentures Payable | February 27, 2016
Short-term Debt [Line Items]
Convertible Debentures Payable, Interest Rate	10.00%	10.00%
Convertible Debentures Payable, Maturity Date	Feb. 27, 2016	Feb. 27, 2016

XML

Basis of Presentation - Additional Information (Detail) (USD $)	Apr. 30, 2013	Oct. 31, 2012
Basis of Presentation [Line Items]
Deficit accumulated during development stage	$ 42,480,889	$ 42,039,223

XML

Summary of Notes (Parenthetical) (Detail) (USD $)	6 Months Ended	12 Months Ended
	Apr. 30, 2013	Oct. 31, 2012
Debt Instrument [Line Items]
Net of accumulated amortization	$ 22,900	$ 22,900
Convertible Note Payable | November 19, 2014
Debt Instrument [Line Items]
Convertible Note Payable, Interest Rate	5.00%	5.00%
Convertible Note Payable, Maturity Date	Nov. 19, 2014	Nov. 19, 2014
Convertible Note Payable | March 27, 2014
Debt Instrument [Line Items]
Convertible Note Payable, Interest Rate	5.00%	5.00%
Convertible Note Payable, Maturity Date	Mar. 27, 2014	Mar. 27, 2014

XML

Warrants Outstanding (Detail)	Apr. 30, 2013	Oct. 31, 2012
Class of Warrant or Right [Line Items]
Warrants outstanding	2,887,085	6,287,085
Issued to consultant August 1, 2009 an exercise price of $0.90
Class of Warrant or Right [Line Items]
Warrants outstanding	287,085	287,085
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, at an exercise price $0.30
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, at an exercise price of $0.50
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, at an exercise price of $0.75
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, at an exercise price of $1.00
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, at an exercise price of $0.75
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued to consultants in September 2011, at an exercise price of $0.10
Class of Warrant or Right [Line Items]
Warrants outstanding	0	1,500,000
Issued to consultants in September 2011, at an exercise price of $0.34
Class of Warrant or Right [Line Items]
Warrants outstanding	0	1,500,000
Issued to consultants in September 2011, at an exercise price of $0.50
Class of Warrant or Right [Line Items]
Warrants outstanding	0	1,000,000
Issued to debenture holders February 2013, at an exercise price of $0.25
Class of Warrant or Right [Line Items]
Warrants outstanding	600,000	0

XML

Net Loss per Share (Tables)

6 Months Ended

Apr. 30, 2013

Earnings Per Share [Abstract]

Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share

The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share (EPS):

	Three Months Ended April 30,				Six Months Ended April 30,
	2013		2012		2013		2012
Weighted-average shares - basic		56,676,166		55,626,166		56,676,166		55,626,166
Effect of dilutive securities		▬		▬		▬		▬
Weighted-average shares - diluted		56,676,166		55,626,166		56,676,166		55,626,166

XML

Changes in Fair Value Of Derivative Liability (Detail) (USD $)	6 Months Ended
	Apr. 30, 2013
Changes In Fair Value Of Derivative Liability [Line Items]
Balance at beginning of period	$ 0
Additions To Derivative Instruments	75,000
Change in fair value of derivative liabilities	(10,781)
Balance at end of period	$ 64,219

XML

Summary of Significant Accounting Policies. (Policies)

6 Months Ended

Apr. 30, 2013

Accounting Policies [Abstract]

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 as of November 1, 2013.

In February 2013, the Financial Accounting Standards Board (“FASB”) issued guidance requiring disclosure of amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present either on the face of the condensed consolidated statements of operations or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts not reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This guidance is effective prospectively for the Company for annual and interim periods beginning January 1, 2013. The Company believes that the impact of this standard has not had a material impact on its consolidated financial statements.

Derivative Instruments

Derivative Instruments

The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the condensed consolidated balance sheets as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date.

XML

Condensed Consolidated Statements of Changes in Equity (Deficiency) (USD $)	Total	Common Stock	Additional Paid-in Capital	Deficit Accumulated During the Development Stage	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interest
Beginning Balance at Oct. 31, 2012	$ (506,753)	$ 543	$ 42,036,498	$ (42,039,223)	$ (166,637)	$ (337,934)
Beginning Balance (in shares) at Oct. 31, 2012		56,676,166
Value of derivative associated with debentures issued in the period	95,760		95,760
Net loss attributable to noncontrolling interest	(2,721)					(2,721)
Comprehensive income, currency translation adjustments	9,510				9,510
Net Loss	(441,666)			(441,666)
Ending Balance at Apr. 30, 2013	$ (845,870)	$ 543	$ 42,132,258	$ (42,480,889)	$ (157,127)	$ (340,655)
Ending Balance (in shares) at Apr. 30, 2013		56,676,166

XML

Nature of Business

6 Months Ended

Apr. 30, 2013

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Nature of Business

1. Nature of Business

CardioGenics Inc. (“CardioGenics”) was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development.

CardioGenics’ business is that of a development-stage company, with a limited history of operations and whose revenues, to date, have been primarily comprised of grant revenue and Scientific Research Tax Credits from government agencies. There can be no assurance that the Company will be successful in obtaining regulatory approval for the marketing of any of the existing or future products that the Company will succeed in developing.

On October 27, 2009, the name of the Company was changed from JAG Media Holdings, Inc. to CardioGenics Holdings, Inc.

XML

Income Taxes

6 Months Ended

Apr. 30, 2013

Income Tax Disclosure [Abstract]

Income Taxes

4. Income Taxes

Based on the Company’s evaluation, management has concluded that there are no significant tax positions requiring recognition in the condensed interim consolidated financial statements.

The Company has incurred losses in Canada since inception, which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of April 30, 2013, approximated $6,750,000 (2012 - $6,301,000) which will expire from 2014 through 2032. All fiscal years as originally filed have been assessed. Claims relating to research and development credits are open for review for the fiscal years ended October 2012, 2011, 2010, 2009, 2008 and 2007 and July 2009.

As of April 30, 2013, the Company had net operating loss carryforwards from US sources of approximately $40,769,000 (2012 - $40,652,000) available to reduce future Federal taxable income which will expire from 2019 through 2032. Returns for the years 2008 through 2012 are yet to be filed.

For the six months ended April 30, 2013 and 2012, the Company’s effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.

XML

Basis of Presentation

6 Months Ended

Apr. 30, 2013

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Basis of Presentation

2. Basis of Presentation

In the opinion of management, the unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the condensed interim consolidated financial position of CardioGenics Holdings Inc. and its subsidiaries under generally accepted accounting principles in the United States (“US GAAP”) as of April 30, 2013, their results of operations for the three and six months ended April 30, 2013 and 2012, and the period from November 20, 1997 (date of inception) to April 30, 2013, changes in comprehensive loss for the three and six months ended April 30, 2013 and 2012 and the period from November 20, 1997 (date of inception) to April 30, 2013, changes in deficiency for the six months ended April 30, 2013 and cash flows for the six months ended April 30, 2013 and 2012, and the period from November 20, 1997 (date of inception) to April 30, 2013. CardioGenics Holdings Inc. and its subsidiaries are referred to together herein as the “Company”. Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these consolidated financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements, notes to consolidated financial statements and the other information in the audited consolidated financial statements of the Company as of October 31, 2012 and 2011 (the “Audited Financial Statements”) included in the Company’s Form 10-K that was previously filed with the SEC on January 29, 2013 and from which the October 31, 2012 consolidated balance sheet was derived.

The results of the Company’s operations for the six months ended April 30, 2013 are not necessarily indicative of the results of operations to be expected for the full year ending October 31, 2013.

The accompanying condensed interim consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at April 30, 2013 of approximately $42.5 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements Management’s plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing.

While the Company believes it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

XML

Derivative Liabilities - Additional Information (Detail) (USD $)	6 Months Ended
	Apr. 30, 2013
Derivative Liabilities [Line Items]
Derivative liability, fair value, gross liability	$ 75,000
Fair value assumptions, exercise price	$ 0.12
Fair value assumptions, risk free interest rate	0.18%
Fair value assumptions, expected term	1 year
Fair value assumptions, expected dividend rate	0.00%
Fair value assumptions, expected volatility rate	170.00%

XML

Debentures Payable (Tables)

6 Months Ended

Apr. 30, 2013

Debt Disclosure [Abstract]

Schedule of Short-term Debt

A summary of the Debentures at April 30, 2013 is as follows:

	April 30, 2013			October 31, 2012
Convertible Debentures Payable, interest at 10% per annum to maturity at February 27, 2016	$	300,393		$	-
Debt Discount - value attributable to conversion feature attached to notes		(95,760	)		-
Total		204,633			-
Less: Current portion		-			-
Total Long-term portion	$	204,633		$	-

XML

Supplemental Disclosure of Cash Flow Information (Tables)

6 Months Ended

Apr. 30, 2013

Supplemental Cash Flow Elements [Abstract]

Cash Flow Supplemental Disclosures

	Six Months Ended
	April 30
	2013		2012
Cash paid during the year for:
Interest	$	6,735	$	9,358
Income taxes	$	▬	$	▬

XML

Advance Payable - Additional Information (Detail) (USD $)	1 Months Ended	6 Months Ended
	May 30, 2013	Apr. 30, 2013
Advance Payable [Line Items]
Advances From Unrelated Third Party	$ 300,000	$ 200,000

XML

Supplemental Disclosure of Cash Flow Information (Detail) (USD $)	6 Months Ended
	Apr. 30, 2013	Apr. 30, 2012
Cash paid during the year for:
Interest	$ 6,735	$ 9,358
Income taxes	$ 0	$ 0

XML

Warrants Outstanding (Parenthetical) (Detail)	6 Months Ended	12 Months Ended
	Apr. 30, 2013	Oct. 31, 2012
Issued to consultant August 1, 2009 an exercise price of $0.90
Class of Warrant or Right [Line Items]
Warrant, issuance date	Aug. 01, 2009	Aug. 01, 2009
Warrant, exchange ratio to common stock	1	1
Warrant, exercise price	0.90	0.90
Warrant, last exercisable date	Jul. 31, 2017	Jul. 31, 2017
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, at an exercise price $0.30
Class of Warrant or Right [Line Items]
Warrant, issue date	2011-08	2011-08
Warrant, exchange ratio to common stock	1	1
Warrant, exercise price	0.30	0.30
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, at an exercise price of $0.50
Class of Warrant or Right [Line Items]
Warrant, issue date	2011-08	2011-08
Warrant, exchange ratio to common stock	1	1
Warrant, exercise price	0.50	0.50
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, at an exercise price of $0.75
Class of Warrant or Right [Line Items]
Warrant, issue date	2011-08	2011-08
Warrant, exchange ratio to common stock	1	1
Warrant, exercise price	0.75	0.75
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, at an exercise price of $1.00
Class of Warrant or Right [Line Items]
Warrant, issue date	2011-08	2011-08
Warrant, exchange ratio to common stock	1	1
Warrant, exercise price	1	1
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, at an exercise price of $0.75
Class of Warrant or Right [Line Items]
Warrant, issue date	2011-08	2011-08
Warrant, exchange ratio to common stock	1	1
Warrant, exercise price	0.75	0.75
Warrant, last exercisable date	Aug. 23, 2016	Aug. 23, 2016
Issued to consultants in September 2011, at an exercise price of $0.10
Class of Warrant or Right [Line Items]
Warrant, issue date	2011-09	2011-09
Warrant, exchange ratio to common stock	1	1
Warrant, exercise price	0.10	0.10
Warrant, last exercisable date	Mar. 20, 2013	Mar. 20, 2013
Issued to consultants in September 2011, at an exercise price of $0.34
Class of Warrant or Right [Line Items]
Warrant, issue date	2011-09	2011-09
Warrant, exchange ratio to common stock	1	1
Warrant, exercise price	0.34	0.34
Warrant, last exercisable date	Mar. 20, 2013	Mar. 20, 2013
Issued to consultants in September 2011, at an exercise price of $0.50
Class of Warrant or Right [Line Items]
Warrant, issue date	2011-09	2011-09
Warrant, exchange ratio to common stock	1	1
Warrant, exercise price	0.50	0.50
Warrant, last exercisable date	Mar. 20, 2013	Mar. 20, 2013
Issued to debenture holders February 2013, at an exercise price of $0.25
Class of Warrant or Right [Line Items]
Warrant, issue date	2013-02	2013-02
Warrant, exchange ratio to common stock	1	1
Warrant, exercise price	0.25	0.25
Warrant, last exercisable date	Feb. 27, 2016	Feb. 27, 2016

XML

Debentures Payable (Detail) (USD $)	Apr. 30, 2013	Oct. 31, 2012
Short-term Debt [Line Items]
Convertible Debentures Payable, interest at 10% per annum to maturity at February 27, 2016	$ 300,393	$ 0
Debt Discount - value attributable to conversion feature attached to notes	(95,760)	0
Total	204,633	0
Less: Current portion	0	0
Total Long-term portion	$ 204,633	$ 0

XML

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Apr. 30, 2013	Oct. 31, 2012
Preferred Stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	150,000,000	150,000,000
Common Stock
Common stock, common shares issued	32,499,239	32,499,239
Common stock, common shares outstanding	32,499,239	32,499,239
Exchangeable Shares
Common stock, common shares issued	24,176,927	24,176,927
Common stock, common shares outstanding	24,176,927	24,176,927

XML

Notes Payable

6 Months Ended

Apr. 30, 2013

Notes Payable [Abstract]

Notes Payable

7. Notes Payable

On November 19, 2012 the Company entered into an agreement (“Line”) with JMJ Financial (“Lender”) whereby the Company may borrow up to $350,000 from the Lender in increments of $50,000. The Line is subject to an original issue discount of $50,000. Advances under the Line (“Notes”) have a maturity date of one year from the date of the advance. If the advance is repaid within three months the advance is interest free. If not repaid within three months, the advance may not be repaid before maturity and carries interest at 5%. The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion. Unless agreed in writing by the parties, at no time will the Lender convert any amount owing under the Line into common stock that would result in the Lender owing more than 4.99% of the common stock outstanding. On March 27, 2013, the Company borrowed $25,000 under this Line.

A summary of the Notes at April 30, 2013 is as follows:

	April 30, 2013			October 31, 2012
Convertible Note Payable, interest at 5% per annum to maturity at November 19, 2014	$	50,000		$	-
Convertible Note Payable, interest at 5% per annum to maturity at March 27, 2014		25,000			-
Debt Discount - value attributable to conversion feature attached to notes, net of accumulated amortization of $22,900		(52,100	)		-
Total		22,900			-
Less: Current portion		22,900			-
Total Long-term portion	$	-		$	-

As described in further detail in Note 8, “Derivative Liabilities”, the Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and as a derivative liability. Upon conversion of the Notes to Common Stock, any remaining unamortized discount is charged to financing expense.

XML

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended		185 Months Ended
	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013
Net Loss	$ (209,859)	$ (391,703)	$ (441,666)	$ (706,672)	$ (42,480,889)
Other comprehensive income (loss), currency translation adjustments	1,085	(22,206)	9,510	12,651	(157,127)
Comprehensive loss	$ (208,774)	$ (413,909)	$ (432,156)	$ (694,021)	$ (42,638,016)

XML

Condensed Consolidated Balance Sheets (USD $)	Apr. 30, 2013	Oct. 31, 2012
Current Assets
Cash and Cash Equivalents	$ 237,435	$ 27,009
Accounts Receivable	255	437
Deposits and Prepaid Expenses	50,989	51,422
Refundable Taxes Receivable	7,149	45,207
Government Grants and Investment Tax Credits Receivable	39,702	80,080
Assets, Current, Total	335,530	204,155
Long-Term Assets
Property and Equipment, net	61,016	67,827
Patents, net	123,118	110,031
Assets, Noncurrent, Total	184,134	177,858
Total Assets	519,664	382,013
Current Liabilities
Accounts Payable and Accrued Expenses	873,516	786,135
Funds Held in Trust for Redemption of Class B Common Shares	4	4
Due to Shareholders	0	100,000
Advance Payable	200,262	0
Current Portion of Capital Lease Obligation	0	2,627
Notes Payable, net of debt discount	22,900	0
Derivative Liability on Notes Payable	64,219	0
Liabilities, Current, Total	1,160,901	888,766
Long-Term Liabilities
Debentures Payable	204,633	0
Long-Term Liabilities	204,633	0
Total Liabilities	1,365,534	888,766
Commitments and Contingencies
Deficiency
Preferred stock; par value $.0001 per share, 50,000,000 shares authorized, none issued	0	0
Common stock; par value $.00001 per share; 150,000,000 shares authorized, 32,499,239 common shares and 24,176,927 exchangeable shares issued and outstanding as at April 30, 2013 and October 31, 2012, respectively	543	543
Additional paid-in capital	42,132,258	42,036,498
Deficit accumulated during development stage	(42,480,889)	(42,039,223)
Accumulated other comprehensive loss	(157,127)	(166,637)
Total deficiency attributable to CardioGenics Holdings Inc.	(505,215)	(168,819)
Non-controlling interest	(340,655)	(337,934)
Total deficiency	(845,870)	(506,753)
Total liabilities and deficiency	$ 519,664	$ 382,013

XML

Issuance of Common Stock - Additional Information (Detail) (USD $)	Apr. 30, 2013	Jan. 17, 2013	Oct. 31, 2012
Issuance Of Common Stock [Line Items]
Common stock, shares authorized	150,000,000	150,000,000	150,000,000
Preferred stock, shares authorized	50,000,000	50,000,000	50,000,000
Common stock, par value	$ 0.00001	$ 0.00001	$ 0.00001
Preferred Stock, par value	$ 0.0001	$ 0.00001	$ 0.0001
Before amendment
Issuance Of Common Stock [Line Items]
Common stock, shares authorized		65,000,000
Preferred stock, shares authorized		5,000,000

XML

Stock Based Compensation (Tables)

6 Months Ended

Apr. 30, 2013

Share-Based Compensation [Abstract]

Summary of Common Stock Options Granted, Forfeited or Expired and Exercised under Plan

The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:

			Weighted
			Average
			Exercise
	Options		Price
Outstanding – October 31, 2011		30,000	$	0.90
Granted		▬		▬
Forfeited/Expired		▬		▬
Exercised		▬		▬
Outstanding – October 31, 2012		30,000	$	0.90
Granted		▬		▬
Forfeited/Expired		▬		▬
Exercised		▬		▬
Outstanding – April 30, 2013		30,000	$	0.90

XML

Supplemental Disclosure of Cash Flow Information

6 Months Ended

Apr. 30, 2013

Supplemental Cash Flow Elements [Abstract]

Supplemental Disclosure of Cash Flow Information

16. Supplemental Disclosure of Cash Flow Information

	Six Months Ended
	April 30
	2013		2012
Cash paid during the year for:
Interest	$	6,735	$	9,358
Income taxes	$	▬	$	▬

XML

Debentures Payable - Additional Information (Detail) (USD $)	6 Months Ended
	Apr. 30, 2013	Jun. 30, 2013	May 30, 2013
Short-term Debt [Line Items]
Debt Instrument Term	3 years
Amount due to shareholders interest rate	10.00%
Debt Instrument, Convertible, Conversion Price	$ 0.25	$ 0.15	$ 0.15

XML

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended
	Apr. 22, 2009
Commitments and Contingencies Disclosure [Line Items]
Former employee related claims	$ 514,000

XML

Summary of Notes (Detail) (USD $)	Apr. 30, 2013	Oct. 31, 2012
Short-term Debt [Line Items]
Debt Discount - value attributable to conversion feature attached to notes, net of accumulated amortization of $22,900	$ (52,100)	$ 0
Total	22,900	0
Less: Current portion	22,900	0
Total Long-term portion	0	0
Convertible Note Payable | November 19, 2014
Short-term Debt [Line Items]
Convertible Note Payable, interest at 5% per annum to maturity	50,000	0
Convertible Note Payable | March 27, 2014
Short-term Debt [Line Items]
Convertible Note Payable, interest at 5% per annum to maturity	$ 25,000	$ 0

XML

Income Taxes - Additional Information (Detail) (USD $)	6 Months Ended
	Apr. 30, 2013	Apr. 30, 2012
CANADA
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards	$ 6,750,000	$ 6,301,000
Operating loss carry forwards expiration period	2014 through 2032	2014 through 2032
UNITED STATES
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards	$ 40,769,000	$ 40,652,000
Operating loss carry forwards expiration period	2019 through 2032	2019 through 2032

XML

Due to Shareholders - Additional Information (Detail) (USD $)	6 Months Ended
	Apr. 30, 2013	Jun. 30, 2013	May 30, 2013	Oct. 31, 2012	Jan. 31, 2013 Shareholder/Directors
Related Party Transaction [Line Items]
Amount due to shareholders					$ 200,000
Due to Shareholders	$ 0			$ 100,000
Debt Instrument Term	3 years
Amount due to shareholders interest rate	10.00%
Debt Instrument, Convertible, Conversion Price	$ 0.25	$ 0.15	$ 0.15
Share Price	$ 0.25

XML

Advance Payable

6 Months Ended

Apr. 30, 2013

Advance Payable [Abstract]

Advance Payable

6. Advance Payable

In April 2013, an unrelated third party advanced $200,000 to the Company as an advance against the purchase of Series B Convertible Debenture Units to be issued after April 30, 2013. The advance is due on demand and carries no interest.

XML

Warrants (Tables)

6 Months Ended

Apr. 30, 2013

Warrants [Abstract]

Warrants Outstanding

Outstanding warrants are as follows:

	April 30, 2013		October 31, 2012
Issued to consultant August 1, 2009, entitling the holder to purchase 1 common share in the company at an exercise price of $0.90 per common share up to and including July 31, 2017		287,085		287,085
Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016		250,000		250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016		250,000		250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016		500,000		500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including March 20, 2013		▬		1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.34 per common share up to and including March 20, 2013		▬		1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including March 20, 2013		▬		1,000,000
Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016		600,000		▬
Total Warrants outstanding		2,887,085		6,287,085

XML

Level of Valuation Inputs Within Fair Value Hierarchy Utilized to Measure Fair Value (Detail) (USD $)	6 Months Ended
	Apr. 30, 2013	Oct. 31, 2012
Defined Benefit Plan Disclosure [Line Items]
Derivative liability - on Notes Payable	$ 64,219	$ 0
Total Increase (Reduction) in Fair Value Recorded	10,781
Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Derivative liability - on Notes Payable	0
Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Derivative liability - on Notes Payable	0
Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Derivative liability - on Notes Payable	$ 64,219

XML

Fair Value Measurements

6 Months Ended

Apr. 30, 2013

Compensation and Retirement Disclosure [Abstract]

Fair Value Measurements

9. Fair Value Measurements

As defined by the Accounting Standard Codification (ASC), fair value measurements and disclosures establish a hierarchy that prioritizes fair value measurements based on the type of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of hierarchy are described below:

· Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities.

· Level 2: Inputs other than quoted market prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets, such as interest rates and yield curves that are observable at commonly-quoted intervals.

· Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions, as there is little, if any, related market activity.

The following table summarizes the financial liabilities measured at fair value on a recurring basis as of April 30, 2013, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value:

	Quoted Prices in								Total Increase (Reduction)
	Active Markets for		Significant Other		Significant				in Fair Value
Balance Sheet	Identical Assets or		Observable Inputs		Unobservable		April 30, 2013		Recorded at
Location	Liabilities (Level 1)		(Level 2)		Inputs (Level 3)		Total		April 30, 2013
Liabilities:
Derivative liability – on Notes Payable	$	-	$	-	$	64,219	$	64,219	$	10,781

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the six month period ended April 30, 2013.

Balance at beginning of period	$	-
Additions to derivative instruments		75,000
Change in fair value of derivative liabilities		(10,781	)
Balance at end of period	$	64,219

XML

Due to Shareholders

6 Months Ended

Apr. 30, 2013

Related Party Transactions [Abstract]

Due to Shareholders

5. Due to Shareholders

During the three months ended January 31, 2013, two shareholder/directors advanced $200,000 to the Company. On February 27, 2013, those advances together with $100,000 advanced by a shareholder to the Company prior to October 31, 2012 were exchanged on a dollar for dollar basis for Series A Convertible Debenture Units (the “Units”). Each unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase an equal number of common shares of the Company’s stock at a price of $0.25 per share exercisable at any time during the term of the warrant.

XML

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended		185 Months Ended
	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013
Cash flows from operating activities
Consolidated Net Loss for the Period	$ (444,387)	$ (711,103)	$ (42,821,544)
Adjustments to reconcile consolidated net loss for the period to net cash used in operating activities
Depreciation and Amortization of Property and Equipment	6,967	9,094	226,711
Amortization of Patent Application Costs	3,429	2,560	22,722
Write-off of Patent Application Costs	0	0	239,530
Amortization of Deferred Consulting Contract Costs	0	0	163,750
Write-off of Goodwill	0	0	12,780,214
Amortization of Deferred Debt Issuance Costs	0	0	511,035
Loss on Extinguishment of Debt	0	0	275,676
Loss (Gain) on Change in Value of Derivative Liability	(10,781)	0	12,410,242
Amortization of Discount on Notes Payable	22,900	0	22,900
Interest Accrued and Foreign Exchange Loss on Debt	0	0	922,539
Unrealized Foreign Currency Exchange Gains	0	0	25,094
Beneficial Conversion Charge included in Interest Expense	0	0	452,109
Common Stock Issued as Employee or Officer/Director Compensation	0	0	2,508,282
Changes in Operating Assets and Liabilities, Net of Acquisition
Accounts Receivable	182	6,094	(255)
Deposits and Prepaid Expenses	433	(457)	(50,200)
Refundable Taxes Receivable	38,058	9,086	(6,285)
Government Grants and Investment Tax Credits Receivable	40,378	(6,121)	(19,640)
Accounts Payable and Accrued Expenses	87,380	36,687	105,603
Advances	200,262	0	200,393
Cash used in operating activities	(55,179)	(654,160)	(7,404,242)
Cash flows from investing activities
Cash Acquired from Acquisition	0	0	195,885
Purchase of Property and Equipment	(156)	(3,893)	(223,646)
Patent Application Costs	(13,087)	(609)	(331,861)
Cash used in investing activities	(13,243)	(4,502)	(359,622)
Cash flows from financing activities
Due to Shareholders	(100,000)	262,500	0
Derivative Liability on Notes Payable	75,000	0	75,000
(Repayment) of Capital Lease Obligations	(2,627)	(13,742)	(43,917)
Due to Director	0	0	725,330
Issue of Debentures	0	0	1,378,305
Issue of Common Shares on Exercise of Stock options	0	0	2,781
Issue of Common Shares on Exercise of Warrants	0	0	45,652
Issue of Common Shares for Cash	0	0	5,886,669
Refund of Share Subscription	0	0	(15,000)
Issue (Redemption) of 10% Senior Convertible Debentures	300,393	0	(94,579)
Cash provided by financing activities	272,766	248,758	7,960,241
Effect of foreign exchange on cash and cash equivalents	6,082	12,653	41,058
Cash and Cash Equivalents
Increase (decrease) in cash and cash equivalents during the period	210,426	(397,251)	237,435
Beginning of Period	27,009	669,202	0
End of Period	237,435	271,951	237,435
Settlement of lawsuit
Adjustments to reconcile consolidated net loss for the period to net cash used in operating activities
Common Stock and Warrants issued	0	0	1,653,800
Services rendered
Adjustments to reconcile consolidated net loss for the period to net cash used in operating activities
Common Stock and Warrants issued	0	0	2,726,262
Stock Options Issued	0	0	192,238
Director and Committee Chairman
Adjustments to reconcile consolidated net loss for the period to net cash used in operating activities
Stock Options Issued	$ 0	$ 0	$ 54,582

XML

Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share (Detail)	3 Months Ended		6 Months Ended
	Apr. 30, 2013	Apr. 30, 2012	Apr. 30, 2013	Apr. 30, 2012
Weighted Average Number of Shares Outstanding [Line Items]
Weighted-average shares - basic	56,676,166	55,626,166	56,676,166	55,626,166
Effect of dilutive securities	0	0	0	0
Weighted-average shares - diluted	56,676,166	55,626,166	56,676,166	55,626,166

XML

Stock Based Compensation - Additional Information (Detail) (Stock Options, USD $)	6 Months Ended
	Apr. 30, 2013	Apr. 30, 2012
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based employee compensation related to stock options	$ 0	$ 0

XML

Nature of Business - Additional Information (Detail)	6 Months Ended
	Apr. 30, 2013
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Entity Incorporation Date Of Incorporation	Nov. 20, 1997
Entity Incorporation State Country Name	Ontario, Canada

XML

Warrants

6 Months Ended

Apr. 30, 2013

Warrants [Abstract]

Warrants

12. Warrants

Outstanding warrants are as follows:

	April 30, 2013		October 31, 2012
Issued to consultant August 1, 2009, entitling the holder to purchase 1 common share in the company at an exercise price of $0.90 per common share up to and including July 31, 2017		287,085		287,085
Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016		250,000		250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016		250,000		250,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016		500,000		500,000
Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including March 20, 2013		▬		1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.34 per common share up to and including March 20, 2013		▬		1,500,000
Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including March 20, 2013		▬		1,000,000
Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016		600,000		▬
Total Warrants outstanding		2,887,085		6,287,085

XML

Derivative Liabilities

6 Months Ended

Apr. 30, 2013

Derivative Liabilities [Abstract]

Derivative Liabilities

8. Derivative Liabilities

Convertible notes - embedded conversion features:

The Notes meet the definition of a hybrid instrument, as defined in ASC 815. The hybrid instrument is comprised of a i) a debt instrument, as the host contract and ii) an option to convert the debentures into common stock of the Company, as an embedded derivative. The embedded derivatives derive their value based on the underlying fair value of the Company’s common stock. The embedded derivatives are not clearly and closely related to the underlying host debt instrument since the economic characteristics and risk associated with these derivatives are based on the common stock fair value.

The Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and a derivative liability. The Company has recognized a derivative liability of $75,000 at April 30, 2013. Accordingly, changes in the fair value of the embedded derivative are immediately recognized in earnings and classified as a gain or loss on the embedded derivative financial instrument in the accompanying condensed consolidated statements of operations. There was no change in the fair value for the six months ended April 30, 2013.

The Company estimated the fair value of the embedded derivatives using a Black Scholes model with the following assumptions: conversion price $0.12 per share according to the agreements; risk free interest rate of .18%; expected life of 1 year; expected dividend of zero; a volatility factor of 170%, as of April 30, 2013. The expected lives of the instruments are equal to the contractual term of the conversion option. The expected volatility is based on the historical price volatility of the Company’s common stock. The risk-free interest rate represents the U.S. Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option.

XML

Commitments and Contingencies

6 Months Ended

Apr. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

15. Commitments and Contingencies

Lawsuits

On April 22, 2009, the Company was served with a statement of claim from a former employee claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company, with an aggregate claim of $514,000. The Company considers all the claims to be without any merit, has already delivered a statement of defense and intends to vigorously defend the action. If the matter eventually proceeds to trial, the Company does not expect to be found liable on any ground or for any cause of action.

XML

Issuance of Common Stock

6 Months Ended

Apr. 30, 2013

Common Stock Issuance [Abstract]

Issuance of Common Stock

13. Issuance of Common Stock

On January 17, 2013, the Company’s articles of incorporation were amended to increase the total number of common and preferred shares authorized for issuance from 65,000,000 shares to 150,000,000 shares and 5,000,000 shares to 50,000,000, respectively, par value $0.00001 per share.

During the six months ended April 30, 2013, the Company issued no common shares.

XML

Document and Entity Information	6 Months Ended
	Apr. 30, 2013	Jun. 12, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	CGNH
Entity Registrant Name	CardioGenics Holdings Inc.
Entity Central Index Key	0001089029
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock Shares Outstanding		32,499,239

XML

Net Loss per Share

6 Months Ended

Apr. 30, 2013

Earnings Per Share [Abstract]

Net Loss per Share

14. Net Loss per Share

The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share (EPS):

	Three Months Ended April 30,				Six Months Ended April 30,
	2013		2012		2013		2012
Weighted-average shares - basic		56,676,166		55,626,166		56,676,166		55,626,166
Effect of dilutive securities		▬		▬		▬		▬
Weighted-average shares - diluted		56,676,166		55,626,166		56,676,166		55,626,166

Basic earnings per share “EPS” and diluted EPS for the three and six months ended April 30, 2013 and 2012 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants representing 2,917,085 and 9,834,969 incremental shares respectively have been excluded from the three and six months ended April 30, 2013 and 2012 computation of diluted EPS as they are antidilutive given the net losses generated.